Icatibant is primarily used in the treatment of hereditary angioedema (HAE), a rare genetic condition characterized by sudden and severe swelling episodes in various parts of the body, including the skin, gastrointestinal tract, and airways. It functions as a bradykinin B2 receptor antagonist, effectively blocking the action of bradykinin, a peptide responsible for the swelling and pain associated with HAE attacks. Administered via subcutaneous injection, Icatibant provides rapid relief from acute attacks, helping to reduce swelling and improve symptoms within hours. Its targeted mechanism of action makes it a valuable therapeutic option for managing this condition, particularly in emergency situations where quick intervention is crucial.